Browsing by Author "Llanos, C."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- ItemCOST - EFFICACY STUDY FOR IPILIMUMAB IN THE CHILEAN MARKET(ELSEVIER SCIENCE INC, 2015) Rovegno, M.; Llanos, C.; Galleguillos, S.; Garrido Lecca, S.
- ItemTumour necrosis factor (TNF)α-308 G/G promoter polymorphism and TNFα levels correlate with a better response to adalimumab in patients with rheumatoid arthritis(2006) Cuchacovich, M.; Soto, L.; Edwardes, M.; Gutierrez, M.; Llanos, C.; Pacheco, D.; Sabugo, F.; Alamo, M.; Fuentealba, C.; Villanueva, L.; Gatica, H.; Schiattino, I.; Salazar, L.; Catalan, D.; Valenzuela, O.Objective: To investigate the influence of -308 tumour necrosis factor-alpha (TNF alpha) promoter polymorphism and circulating TNF alpha levels in the clinical response to adalimumab treatment in patients with rheumatoid arthritis (RA).